Getting a novel drug to market is the endgame for many in biopharma but moving through the clinic without attracting the interest of a larger developer can be considered a slur. Figuring out whether these unencumbered projects are rare gems or fools’ gold is a major challenge, for both investors and pipeline-hungry partners.
Unpartnered Assets: On The Shelf Or Hidden Treasure?
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.

More from Business Strategy
More from In Vivo
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.